Breaking News

Macquarie-Led Group to Buy Louisiana Utility Cleco for $3.4 Billion
Tweet TWEET

Algeta - Notice of Annual General Meeting 2013

Algeta - Notice of Annual General Meeting 2013 
OSLO, NORWAY -- (Marketwire) -- 03/19/13 --  Algeta ASA (OSE:
ALGETA), a company focused on the
development of novel targeted
cancer therapeutics, announces its Annual General
Meeting 2013: 
Algeta's Annual General Meeting will be held on 11 April 2013 at
16:00 hours
(CET) at the offices of Algeta ASA at Kjelsasveien 172A,
Oslo, Norway. 
Please find attached the Notice of Algeta ASA's Annual General
Meeting, proposed
amended charter for the nomination committee, and
attendance slip and proxy form. These are, together with the annual
report, also available on www.algeta.com in the Investor section. 
### 
About Algeta 
Algeta is a company focused on developing novel targeted therapies
for patients
with cancer based on its alpha-pharmaceutical platform.
The Company is headquartered in Oslo, Norway, and has a US
subsidiary, Algeta US, LLC, based in Cambridge, MA performing
commercial marketing operations in the US. Algeta is
listed on the
Oslo Stock Exchange (Ticker: ALGETA). For more information
please
visit www.algeta.com. 
Notice of Attendance of Annual General Meeting in Algeta ASA:
http://hugin.info/134655/R/1686069/552595.pdf 
Attendance and proxy form:
http://hugin.info/134655/R/1686069/552597.pdf 
Proposed amended charter for the Nomination Committee:
http://hugin.info/134655/R/1686069/552596.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and 
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
originality of the information contained therein. 
Source: Algeta ASA via Thomson Reuters ONE [HUG#1686069] 
For further information, please contact: 
Mike Booth / Renate Birkeli
Communications & Corporate Affairs
+47 23 00 67 32
ir@algeta.com 
Media enquiries: 
Mark Swallow
Citigate Dewe Rogerson
+44 207 638 9571
mark.swallow@citigatedr.co.uk 
Knut Ekern
Gambit Hill & Knowlton
+47 22 04 82 00
knut.ekern@hkstrategies.com 
Kari Watson
MacDougall Biomedical Communications
+1 781 235 3060
kwatson@macbiocom.com 
US investor enquiries: 
Tricia Swanson
The Trout Group
+1 646 378 2953
tswanson@troutgroup.com
 
 
Press spacebar to pause and continue. Press esc to stop.